Vindico Medical Education
MedEdTalks - GastroenterologyEpisodes
Episodes of MedEdTalks
Mark All
Search Episodes...
In this podcast, expert clinicians will discuss diet considerations and targeted therapy for treatment of EoE.
In this podcast, expert clinicians will discuss the role of steroids and PPIs for treatment of EoE.
In this podcast, expert clinicians will discuss best practices for the differential diagnosis of EoE.
In this podcast, expert clinicians discuss the latest updates on anti-integrin therapy and S1P receptor modulators in IBD management.
In this podcast, expert clinicians discuss the latest updates on JAK inhibition in IBD management.
In this podcast, expert clinicians discuss the latest updates on anti-IL-12/23 therapy in IBD management.
In this podcast, expert clinicians discuss the latest updates on anti-TNF therapy in IBD management.
In this podcast, expert clinicians compare the immunogenicity of available biologic therapies and explore options for managing patients who develop anti-drug antibodies.
In this podcast, expert clinicians review the variety of extraintestinal manifestations seen in patients with IBD, discussing strategies for assessment and management.
In this podcast, experts review appropriate applications of monotherapy and combination therapy and how to position particular therapies based on disease and patient characteristics.
In this podcast, expert clinicians will discuss the shift from symptom-based management to a treat-to-target paradigm, detailing important treatment aims and reviewing the mechanisms of action of available therapies.
In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD.
In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-integrin and S1P-1 receptor modulators, that are in late-stage development for treating moderate to severe CD.
In this podcast, expert clinicians will discuss emerging therapies with unique mechanisms of action that can improve the treatment of moderate to severe Crohn’s disease.
Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 InhibitorsInflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therap
Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patie
Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patie
Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patie
Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patie
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us